COMMUNIQUÉS West-GlobeNewswire

Herantis Pharma has initiated patient recruitment and consented first patient in CDNF study in Parkinson's disease

27/09/2017 - 08:00

Herantis Pharma has initiated patient recruitment and consented first patient in CDNF study in Parkinson's disease Herantis Pharma Plc Company release 27 Sep 2017 at 9:00 am Herantis Pharma Plc ("Herantis") has [...]

Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to Patients

27/09/2017 - 08:00

Earlier than expected results demonstrate absorption occurs primarily in the lungs following inhaled administration LONDON, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma [...]

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

27/09/2017 - 07:30

Generally well-tolerated with no clinically relevant safety signals in Phase 1 study At the highest dose level, 5 out of 6 patients (83%) reached an improvement of at least 50% in atopic dermatitis symptoms (EASI-50) by [...]

VIFOR PHARMA EXPANDS EXCLUSIVE LICENSE AGREEMENT FOR THE COMMERCIALISATION OF MIRCERA® IN THE US

27/09/2017 - 06:56

PRESS RELEASE This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]

Communiqué : Le projet de rapprochement entre Essilor et Luxottica se poursuit

26/09/2017 - 18:15

Le projet de rapprochement entre Essilor et Luxottica se poursuit Version PDF du communiqué Charenton-le-Pont, France et Milan, Italie (le 26 septembre 2017) - Essilor et Luxottica confirment que la Commission [...]

New Release: Further progress in the proposed combination between Essilor and Luxottica

26/09/2017 - 18:15

Further progress in the proposed combination between Essilor and Luxottica PDF Version of the news release Charenton-le-Pont, France and Milan, Italy, September 26, 2017 - Essilor and Luxottica today confirm that the [...]

Change in Nexstim Plc's Management Team

26/09/2017 - 18:00

Company announcement, Helsinki, 26 September 2017 at 7:00 pm Change in Nexstim Plc's Management Team Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing [...]

GUERBET : 2017 half-year results

26/09/2017 - 17:47

2017 half-year results > Satisfactory activity growth > Ebitda level above 15% Villepinte, September 26, 2017 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging [...]

GUERBET : résultats semestriels 2017

26/09/2017 - 17:47

Résultats semestriels 2017 > Progression satisfaisante de l'activité > Un niveau d'Ebitda supérieur à 15% Villepinte, le 26 septembre 2017 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de [...]

Mérieux Développement announces the completion of a Series B financing into PhysioAssist, to commercialize SimeoxTM as the new standard for airway clearance in Europe and internationally

26/09/2017 - 14:55

Press Release Fundraising - Medical Device - Cystic Fibrosis / COPD Mérieux Développement announces the completion of a Series B financing into PhysioAssist, to commercialize Simeox TM as the new standard for airway [...]

PhysioAssist raises 6 million euros in a Series B financing, to commercialize SimeoxTM as the new standard for airway clearance in Europe and internationally

26/09/2017 - 14:55

Press Release Fundraising - Medical Device - Cystic Fibrosis / COPD PhysioAssist raises 6 million euros in a Series B financing, to commercialize Simeox TM as the new standard for airway clearance in Europe and [...]

Auris Medical Provides Board of Directors Update

26/09/2017 - 14:30

Zug, Switzerland, September 26, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, announced today [...]

AroCell AB: AroCell Research Poster on TK1 / TK 210 ELISA in Prostate Cancer has been accepted for presentation at the UK National Cancer Research Institute (NCRI) Annual Meeting November 2017

26/09/2017 - 11:00

AroCell AB (publ) announces today that a research poster submitted by Jagarlamudi K.K. et al. entitled" AroCell TK 210 ELISA may complement pro PSA and the prostate health index in differentiating non-cancerous from [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

26/09/2017 - 09:00

FIT Biotech Oy Company release September 26, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]

AUTOLUS LIMITED: Autolus Secures US$80 million Series C Funding

26/09/2017 - 08:00

Autolus Secures US$80 million Series C Funding Proceeds will be used to establish clinical proof of concept for three novel haematological cancer programs London, 26 September 2017 - Autolus Limited, a clinical-stage [...]

MITHRA SIGNS COMMERCIAL AGREEMENT WITH BRAZILIAN LEADER IN WOMEN'S HEALTH LIBBS FOR ESTELLE® IN BRAZIL

26/09/2017 - 07:30

PRESS RELEASE MIThRA SIGNS commercial agreement with Brazilian LEADER IN WOMEN's HEALTH LIBBS for Estelle® in Brazil 20-year partnership agreement expected to generate a EUR 20 million upfront milestone, as well as [...]

Nestlé details value creation plans at annual investor seminar

26/09/2017 - 07:16

This press release is also available in Français (pdf) and Deutsch (pdf) ....................................... Vevey, September 26, 2017 Nestlé details value creation plans at annual investor seminar Confirms mid- [...]

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

26/09/2017 - 07:00

Interim data expected in H2 2018 September 26, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated [...]

ProLynx annonce l'octroi d'une subvention SBIR pour développer une nouvelle technologie pour les agonistes doubles de récepteurs

26/09/2017 - 00:27

SAN FRANCISCO, le 26 septembre 2017 (GLOBE NEWSWIRE) - ProLynx a annoncé aujourd'hui qu'elle s'est vue attribuer une subvention Small Business Innovation Research (SBIR) du NIH pour étendre sa plateforme technologique [...]